MicroCaps Making Major Moves: DJT, BNOX, ELAB, PETV, RJDG in High-Growth MarketsTrump Media (
NASDAQ: DJT) saw a sharp spike on Election Day as traders speculated that a second Trump presidency could boost business. Often viewed as a proxy for Trump’s White House chances, DJT attracted heavy retail interest, particularly on WallStreetBets, where GameStop (
NYSE: GME) was introduced and gained momentum. This rally could set the stage for other micro-cap stocks highlighted here.
Small-Cap Nasdaq Stocks to Watch Now! VTAK, BNOX, INBS, DYAI, KAVLNumerous small-cap firms listed on NASDAQ could present significant value for investors. This article offers a swift overview of five small-cap stocks on NASDAQ that might be worth considering for inclusion in watch lists.
Imminent Phase 3 Trials To Treat PTSD And SAD Send Bionomics Ltd. Stock Higher By Over 60% Since August ($BNOX)Bionomics Limited (Nasdaq: BNOX) (ASX: BNO) shares are attracting investor attention. And rightly so, noting that the company is nearing the commencement of potentially two near-term Phase 3 trials to treat critical unmet medical needs. The first to enter the Phase 3 arena could be the company's drug candidate to treat Post Traumatic Stress Disorder (PTSD), a logical presumption considering that BNOX announced in August that the last patient visit had been completed in its Phase 2 ATTUNE study. Topline results from Phase 2b are expected this month.
Bionomics Shares Soar 65% Since August Ahead Of Commencing Planned Phase III Trial To Treat PTSD And SAD ($BNOX)Bionomics Limited (Nasdaq: BNOX) (ASX: BNO) shares have kicked into rally mode, surging by over 65% since August 22nd to score an intra-week high thus far of $1.98. The rally is deserved, with the fuse lit after BNOX announced that the last patient visit had been completed in its Phase 2 ATTUNE study in Post-Traumatic Stress Disorder ("PTSD"). Topline results are expected to be released by the end of September. Reaching that milestone isn't the only thing attracting investors' attention. Bionomics also disclosed expectations for its End of Phase 2 (EoPh2) meeting with the FDA in September to review results from its Phase 2 PREVAIL study in patients with Social Anxiety Disorder (SAD). Leaving that meeting could include details putting another milestone in play. Specifically, a more determinant date to commence a proposed Phase 3 registrational trial.
